Exact Sciences Reports Strong Q4 & Full-Year 2025 Results Amidst Pending Acquisition
EXAS has more than doubled off its 52-week low of $38.812.
Summary
Exact Sciences announced robust fourth quarter and full-year 2025 financial results, including significant revenue growth and improved cash flow, as the company approaches a shareholder vote on its acquisition by Abbott Laboratories.
Key Events · Earnings and Guidance · EXAS
-
Strong Q4 2025 Revenue Growth
Total revenue increased 23% to $878 million in Q4 2025, driven by strong performance in both Screening and Precision Oncology segments.
-
Significant Full-Year 2025 Financial Improvement
Full-year revenue reached $3.25 billion (up 18%), with operating cash flow increasing 133% to $491 million and free cash flow surging 379% to $357 million.
-
Reduced Net Loss
The full-year 2025 net loss significantly improved to $208 million compared to $1.028 billion in 2024.
-
Context of Pending Merger
These results precede a shareholder vote on February 20, 2026, for the proposed acquisition by Abbott Laboratories at $105.00 per share, with the company's stock currently trading near this price.
Analysis · EXAS · Industrial Applications And Services
Exact Sciences reported strong financial performance for Q4 and full-year 2025, highlighted by a 23% increase in Q4 revenue to $878 million and an 18% full-year revenue increase to $3.25 billion. The company also demonstrated substantial improvements in profitability and cash generation, with full-year operating cash flow up 133% to $491 million and free cash flow surging 379% to $357 million. While the company still reported a net loss, the full-year loss significantly narrowed compared to the prior year. These positive results reinforce the company's operational strength and come just days before a critical shareholder meeting on February 20, 2026, to vote on the proposed acquisition by Abbott Laboratories for $105.00 per share. The stock is currently trading near this acquisition price, suggesting the market largely anticipates the deal's completion.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXAS was trading at $103.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.7B. The 52-week trading range was $38.81 to $103.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.